title: [Leukinferon in immunological correction of acute inflammatory diseases of the abdominal organs].
abstract: Addition of (intramuscular+intravenous) leukinferon (LF) to the schemes for the treatment of acute peritonitis promoted a more rapid positive development of the time course of clinical signs and decreasing of leukocytosis in the presence of a pronounced tendency to normalization of the main immunological indices i. e. the counts of differential T-lymphocytes and T-helper cells. There was also activation of neutrophil phagocytic function. A rapid decrease in objective signs of endotoxicosis was recorded: the intoxication leukocytic index and the level of medium-mass molecules. In parallel with the decrease in the intoxication leukocytic index, there was a decrease in cytosis of the peritoneal exudate. The use of LF in the treatment of elderly patients with acute cholecystitis eliminated the clinical signs and normalized the main laboratory indices without surgical interventions which allowed one to make a planned operation with the minimum risk.
authors.forename: V V
authors.initials: VV
authors.lastname: Strusov
authors.forename: V P
authors.initials: VP
authors.lastname: Kuznetsov
authors.forename: D L
authors.initials: DL
authors.lastname: Beliaev
authors.forename: A A
authors.initials: AA
authors.lastname: Babaiants
authors.forename: R M
authors.initials: RM
authors.lastname: Khusainov
authors.forename: L A
authors.initials: LA
authors.lastname: Zueva
authors.forename: A V
authors.initials: AV
authors.lastname: Protasov
authors.forename: A G
authors.initials: AG
authors.lastname: Balianskiĭ
authors.forename: G S
authors.initials: GS
authors.lastname: Rybakov
authors.forename: N V
authors.initials: NV
authors.lastname: Tsvetaeva
mesh_terms: D000208:Acute Disease; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D002764:Cholecystitis / Q000276:immunology / Q000628:therapy*; D016207:Cytokines / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D009504:Neutrophils / Q000187:drug effects* / Q000276:immunology; D010538:Peritonitis / Q000276:immunology / Q000628:therapy*; D010587:Phagocytosis / Q000187:drug effects* / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D016207:Cytokines; D004338:Drug Combinations; D007370:Interferon Type I; C062252:leukinferon
vernacular_title: Immunokorrektsiia leĭkinferonom pri ostrykh vospalitel'nykh zabolevaniiakh organov briushnoĭ polosti.